Matthew Walls: CARDIO inCode-Score Presented at AHA25
Matthew Walls, Chief Executive Officer at GENinCode, shared on LinkedIn:
”We are delighted to announce another milestone for CARDIO inCode-Score (polygenic risk score) presented at this weekend’s American Heart Association (AHA) Scientific Sessions Conference in New Orleans. The presentation from Kaiser Permanente showed the latest ASCVD clinical prediction tool ‘PREVENT, was enhanced by the inclusion CARDIO inCode-Score (PRS) providing improved accuracy in personalised risk assessment for prevention of coronary heart disease (CHD). The ASCVD risk prediction tool ‘PREVENT’ estimates a persons risk of developing heart disease.
The presentation showed that integrating CARDIO inCode-Score with PREVENT improves prediction of CHD events. The benefits were particularly evident amongst borderline and intermediate PREVENT risk individuals, where there is uncertainty in clinical decision-making regarding statin initiation or intensification.
We have been working with Kaiser Permanente on the clinical research and development of CARDIO inCode-Score (PRS) for over 15 years. This multi-ancestry population study on over 60,000 individuals, 30-74 years of age with follow up over 14 years, is the latest in a series of clinical utility publications from Kaiser Permanente Departments of Research and Cardiology. Our thanks to Dr. Jamal Rana and Dr. Carlos Iribarren for leading this clinical research and to co-authors Dr. Meng Lu, Dr. Martha Gulati, Dr. Nathan Wong, Dr. Roberto Elosua and our clinical advisory team for championing the inclusion of genetic risk assessment in CHD risk assessment.
CARDIO inCode-Score is a clinically validated, commercially available polygenic risk score using DNA extracted from a simple saliva or blood sample. The test has been designed and optimized for multi-ethnic population-based risk prediction and primary prevention of CHD across international healthcare systems.”
Stay updated with Hemostasis Today.
-
Dec 16, 2025, 16:56Kathryn Mikkelsen on The Beat: Vasculearn Network’s Newsletter for Clot Survivors
-
Dec 16, 2025, 16:50Raul Santos on Sex-Specific Biology and Plasma Fructose Levels in Cardiovascular Risk
-
Dec 16, 2025, 16:34Mads Krogsgaard Thomsen on Novo Nordisk Haemophilia Foundation’s Support for Haemoglobinopathies
-
Dec 16, 2025, 16:22Leonardo Furtado Freitas Presents a Rare Hemorrhagic Hemangioblastoma Case
-
Dec 16, 2025, 16:14Nicolas Gendron on Sustainability in Anticoagulation and DOACs
-
Dec 16, 2025, 15:39Reza Shojaei: Every Expired Unit of Blood Tells a Story
-
Dec 16, 2025, 14:03Francesco Lo Monaco on Rethinking Blood Pressure: The Major Problem with How We Understand It
-
Dec 16, 2025, 14:03Marilena Vrana Urges EU Policymakers to “Keep Patients at the Centre” of Critical Medicines Act
-
Dec 16, 2025, 14:02Even Distribution of Protective Hemoglobin Prevents Sickle Cell Symptoms